LYR-210

About Lyra Therapeutics

Lyra Therapeutics is a clinical-stage biotechnology company with a singular mission: to transform the treatment of chronic rhinosinusitis (CRS) through targeted, long-acting local therapies. The company's core achievement is the development of a proprietary drug-eluting nasal mesh platform, which has advanced its lead candidate, LYR-210, into Phase 3 clinical trials. Lyra's strategy is to address the significant unmet need in the underserved CRS market by providing a durable, procedure-based solution that overcomes the limitations of current systemic and topical treatments. Success hinges on the clinical and regulatory success of LYR-210, which represents the company's primary near-term value driver.

Therapeutic Areas

Other Chronic Rhinosinusitis (CRS) Drugs